IMVT

SEC source: 0001764013-21-000068 · wf-form4_162810753247468.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 703,113

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: 37.5% of the RSUs will vest on January 1, 2022 and the remainder of the RSUs will vest on August 3, 2023, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001104659-21-099083 · tm2123817-2_4seq1.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,388,664

F1 · kind: On August 2, 2021, Roivant and Immunovant, Inc. ("Immunovant") entered into a Share Purchase Agreement pursuant to which Roivant purchased 17,021,276 shares of Immunovant's common stock for an aggregate purchase price of $200,000,000, in cash, representing a per share price of $11.75.

F1 · price: On August 2, 2021, Roivant and Immunovant, Inc. ("Immunovant") entered into a Share Purchase Agreement pursuant to which Roivant purchased 17,021,276 shares of Immunovant's common stock for an aggregate purchase price of $200,000,000, in cash, representing a per share price of $11.75.

SEC source: 0001764013-21-000056 · wf-form4_162376178125938.xml · derivative · entry 3

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,320

Underlying: Common Stock · 369,320 shares

Expires 2031-06-11

F4 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 13, 2022 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000056 · wf-form4_162376178125938.xml · nonDerivative · entry 2

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,045

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F3 · shares: The RSUs vest in their entirety on December 31, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000056 · wf-form4_162376178125938.xml · nonDerivative · entry 1

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,674

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 13, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000045 · wf-form4_161650431840974.xml · derivative · entry 2

MIGAUSKY GEORGE V · CIK 0001134365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires 2031-03-19

F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000045 · wf-form4_161650431840974.xml · nonDerivative · entry 1

MIGAUSKY GEORGE V · CIK 0001134365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,200

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

F2 · balance_after: 20,000 shares are the result of a pro rata distribution from Health Sciences Holdings, LLC, of which the Reporting Person was a member of Health Sciences Acquisition Corporation's board of directors.

SEC source: 0001764013-21-000044 · wf-form4_161650408026344.xml · derivative · entry 2

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,900

Underlying: Common Stock · 28,900 shares

Expires 2031-03-19

F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000044 · wf-form4_161650408026344.xml · nonDerivative · entry 1

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,600

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

SEC source: 0001764013-21-000043 · wf-form4_161650399568493.xml · derivative · entry 2

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires 2031-03-19

F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000043 · wf-form4_161650399568493.xml · nonDerivative · entry 1

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,200

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

SEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires 2031-03-19

F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,200

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

SEC source: 0001764013-21-000041 · wf-form4_161650380299067.xml · derivative · entry 2

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires 2031-03-19

F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000041 · wf-form4_161650380299067.xml · nonDerivative · entry 1

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,200

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

SEC source: 0001764013-21-000040 · wf-form4_161650359586006.xml · derivative · entry 2

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464,700

Underlying: Common Stock · 464,700 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000040 · wf-form4_161650359586006.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,500

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000039 · wf-form4_161650350410303.xml · derivative · entry 2

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,000

Underlying: Common Stock · 162,000 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000039 · wf-form4_161650350410303.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,200

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000038 · wf-form4_161650338493193.xml · derivative · entry 2

Elliott Michael James · CIK 0001822515 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,300

Underlying: Common Stock · 342,300 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000038 · wf-form4_161650338493193.xml · nonDerivative · entry 1

Elliott Michael James · CIK 0001822515 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,600

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000037 · wf-form4_161650328116144.xml · derivative · entry 2

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,300

Underlying: Common Stock · 342,300 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000037 · wf-form4_161650328116144.xml · nonDerivative · entry 1

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,365

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000036 · wf-form4_161650314745187.xml · derivative · entry 2

Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,100

Underlying: Common Stock · 191,100 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000036 · wf-form4_161650314745187.xml · nonDerivative · entry 1

Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,500

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · derivative · entry 3

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,300

Underlying: Common Stock · 342,300 shares

Expires 2031-03-19

F4 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · nonDerivative · entry 2

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,365

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F3 · shares: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.

SEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · nonDerivative · entry 1

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,600

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000006 · wf-form4_161161076317026.xml · derivative · entry 2

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2031-01-22

F3 · derivative.exercise_date: Shares underlying the option vest over four years, with 25% of the shares underlying the option vesting on January 11, 2022, and the remainder of shares underlying the option vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000006 · wf-form4_161161076317026.xml · nonDerivative · entry 1

Jain Rita · CIK 0001707797 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on January 11, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001104659-20-106546 · a4.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,367,388

F1 · kind: On December 18, 2019 (the "Closing Date"), Immunovant Sciences Ltd. ("ISL") and Health Sciences Acquisition Corporation ("HSAC") closed the transactions contemplated by a Share Exchange Agreement, dated as of September 29, 2019 (the "Agreement"), pursuant to which HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for shares of common stock of HSAC ("Common Stock"), and ISL became a wholly owned subsidiary of HSAC (the "Transaction"). At closing of the Transaction, HSAC changed its name to Immunovant, Inc. (the "Company").

F2 · kind: Pursuant to the terms of the Agreement and as part of the Transaction, Roivant received, among other consideration, certain rights to receive additional shares of Common Stock upon the achievement of certain milestones, as described in the Agreement (the "Earnout Rights"), including 8,773,969 shares of Common Stock if the volume weighted average sale price of the Common Stock equaled or exceeded $31.50 for any 20 trading days within a 30-day trading period during the period starting on the Closing Date and ending on March 31, 2025 (the "Milestone"). On September 17, 2020, the Milestone was achieved and Roivant became entitled to receive 8,773,969 shares of Common Stock as additional consideration for the Transaction and without the need for any additional consideration. Roivant's Earnout Rights became fixed and irrevocable on the Closing Date.

F1 · price: On December 18, 2019 (the "Closing Date"), Immunovant Sciences Ltd. ("ISL") and Health Sciences Acquisition Corporation ("HSAC") closed the transactions contemplated by a Share Exchange Agreement, dated as of September 29, 2019 (the "Agreement"), pursuant to which HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for shares of common stock of HSAC ("Common Stock"), and ISL became a wholly owned subsidiary of HSAC (the "Transaction"). At closing of the Transaction, HSAC changed its name to Immunovant, Inc. (the "Company").

F2 · price: Pursuant to the terms of the Agreement and as part of the Transaction, Roivant received, among other consideration, certain rights to receive additional shares of Common Stock upon the achievement of certain milestones, as described in the Agreement (the "Earnout Rights"), including 8,773,969 shares of Common Stock if the volume weighted average sale price of the Common Stock equaled or exceeded $31.50 for any 20 trading days within a 30-day trading period during the period starting on the Closing Date and ending on March 31, 2025 (the "Milestone"). On September 17, 2020, the Milestone was achieved and Roivant became entitled to receive 8,773,969 shares of Common Stock as additional consideration for the Transaction and without the need for any additional consideration. Roivant's Earnout Rights became fixed and irrevocable on the Closing Date.

SEC source: 0001764013-20-000037 · wf-form4_160020415457284.xml · nonDerivative · entry 1

Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001104659-20-102701 · a4.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,593,419

SEC source: 0001764013-20-000031 · wf-form4_159925338889934.xml · derivative · entry 1

Elliott Michael James · CIK 0001822515 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2030-09-04

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 24, 2021, and the remainder vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029944 · doc4.xml · derivative · entry 3

MIGAUSKY GEORGE V · CIK 0001134365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029944 · doc4.xml · nonDerivative · entry 1

MIGAUSKY GEORGE V · CIK 0001134365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,700

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

SEC source: 0001209191-20-029941 · doc4.xml · derivative · entry 2

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2020-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029941 · doc4.xml · nonDerivative · entry 1

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,700

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

SEC source: 0001209191-20-029936 · doc4.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029936 · doc4.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,700

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

SEC source: 0001209191-20-029934 · doc4.xml · derivative · entry 2

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029934 · doc4.xml · nonDerivative · entry 1

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,700

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

SEC source: 0001209191-20-029932 · doc4.xml · derivative · entry 2

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,600

Underlying: Common Stock · 42,600 shares

Expires 2030-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029932 · doc4.xml · nonDerivative · entry 1

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

SEC source: 0001209191-20-029930 · doc4.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,500

Underlying: Common Stock · 180,500 shares

Expires 2030-05-14

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029928 · doc4.xml · derivative · entry 1

MIDDLEKAUFF W BRADFORD · CIK 0001214501 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,600

Underlying: Common Stock · 142,600 shares

Expires 2030-05-14

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029926 · doc4.xml · derivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,700

Underlying: Common Stock · 430,700 shares

Expires 2030-05-14

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029924 · doc4.xml · derivative · entry 1

Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 319,700

Underlying: Common Stock · 319,700 shares

Expires 2030-05-14

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001104659-20-061795 · a4.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,213,419

F1 · kind: On December 18, 2019 (the "Closing Date"), Immunovant Sciences Ltd. ("ISL") and Health Sciences Acquisition Corporation ("HSAC") closed the transactions contemplated by a Share Exchange Agreement, dated as of September 29, 2019 (the "Agreement"), pursuant to which HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for shares of common stock of HSAC ("Common Stock"), and ISL became a wholly owned subsidiary of HSAC (the "Transaction"). At closing of the Transaction, HSAC changed its name to Immunovant, Inc. (the "Company").

F2 · kind: Pursuant to the terms of the Agreement and as part of the Transaction, Roivant received, among other consideration, certain rights to receive additional shares of Common Stock upon the achievement of certain milestones, as described in the Agreement (the "Earnout Rights"), including 8,773,969 shares of Common Stock if the volume weighted average sale price of the Common Stock equaled or exceeded $17.50 for any 20 trading days within a 30-day trading period during the period starting on the Closing Date and ending on March 31, 2023 (the "Milestone"). On May 12, 2020, the Milestone was achieved and Roivant became entitled to receive 8,773,969 shares of Common Stock as additional consideration for the Transaction and without the need for any additional consideration. Roivant's Earnout Rights became fixed and irrevocable on the Closing Date.

F1 · price: On December 18, 2019 (the "Closing Date"), Immunovant Sciences Ltd. ("ISL") and Health Sciences Acquisition Corporation ("HSAC") closed the transactions contemplated by a Share Exchange Agreement, dated as of September 29, 2019 (the "Agreement"), pursuant to which HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for shares of common stock of HSAC ("Common Stock"), and ISL became a wholly owned subsidiary of HSAC (the "Transaction"). At closing of the Transaction, HSAC changed its name to Immunovant, Inc. (the "Company").

F2 · price: Pursuant to the terms of the Agreement and as part of the Transaction, Roivant received, among other consideration, certain rights to receive additional shares of Common Stock upon the achievement of certain milestones, as described in the Agreement (the "Earnout Rights"), including 8,773,969 shares of Common Stock if the volume weighted average sale price of the Common Stock equaled or exceeded $17.50 for any 20 trading days within a 30-day trading period during the period starting on the Closing Date and ending on March 31, 2023 (the "Milestone"). On May 12, 2020, the Milestone was achieved and Roivant became entitled to receive 8,773,969 shares of Common Stock as additional consideration for the Transaction and without the need for any additional consideration. Roivant's Earnout Rights became fixed and irrevocable on the Closing Date.

SEC source: 0001104659-20-048301 · a4.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,439,450